Top

Mariana Chavez Mac Gregor, M.D., MSC

Department of Health Services Research, Division of Cancer Prevention and Population Sciences

Meet Mariana Chavez Mac Gregor, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas

Education & Training

Degree-Granting Education

2004	Netherlands Institute of Health and Sciences, Rotterdam, NL, M.Sc. in Clinical Epidemiology
2003	Universidad Nacional Autónoma de México, Facultad de Medicina, Mexico City, MX, MD

Postgraduate Training

2008-2011	Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2006-2008	Clinical Residency, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, Missouri
2005-2006	Clinical Internship, Internal Medicine, Barnes-Jewish Hospital/Washington University School of Medicine, St. Louis, Missouri

Board Certifications

2024	Medical Oncology
2016	Medical Oncology ( Mexican Board of Oncology)
2011	Medical Oncology
2008	Internal Medicine

Experience & Service

Academic Appointments

Associate Professor, Tenured, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2023

Associate Professor, Tenured, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2023

Associate Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019

Associate Professor, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019

Assistant Professor, Tenure Track, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017

Assistant Professor, Tenure Track, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017

Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2014

Administrative Appointments/Responsibilities

Executive Officer for International Affairs, SWOG, Houston, TX, 2021 - Present

Director, Education Programs, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present

Other Appointments/Responsibilities

Council Member, Yellow For Pink by Kendra Scott, Austin, TX, 2022 - Present

Panel Member, Advanced Breast Cancer (ABC6) Consensus, Lisbon, 2021 - 2021

Member, ASCO Ethics Committee, Alexandria, VA, 2021 - Present

Board of Directors, ASCO, Alexandria, VA, 2021 - Present

Member, ASCO's Equity Diversity and Inclusion (EDI) Strategic Priorities Task Force, Alexandria, VA, 2021 - Present

Ex-Officio Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 2020 - 2021

Co-Chair, ASCO Breast Cancer Guidelines Advisory Group, Alexandria, VA, 2020 - 2021

Member, AJCC Breast Cancer Expert Panel for the 9th Version of AJCC Cancer Staging, 2020 - Present

Past Chair, ASCO Clinical Practice Guidelines, Alexandria, VA, 2019 - 2020

Member, ASCO Stratified Resource Guidelines Advisory Group, Alexandria, VA, 2019 - Present

Chair, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 2019 - 2020

Member, ASCO eLearning Review Panel (Breast Cancer), Alexandria, VA, 2019 - Present

Member, ASCO Women’s Networking Center Taskforce, Alexandria, VA, 2019 - Present

Liaison - Inbound, Cancer Committee, College of American Pathologists (CAP) Board of Governors, Northfield, IL, 2019 - 2021

Member, Chemotherapy for Women with Advanced HER-2 negative Breast Cancer Guideline Update, ASCO, Alexandria, VA, 2019 - 2019

Board of Directors, Legacy Community Health, Houston, TX, 2018 - Present

Board of Directors, The Hope Foundation, Houston, TX, 2018 - Present

Member, ASCO Leadership Development Program, Alexandria, VA, 2018 - 2019

Chair, ASCO Clinical Practice Guidelines, Alexandria, VA, 2018 - 2019

Member, Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update, ASCO, Alexandria, VA, 2018 - 2019

Chair Elect, ASCO Clinical Practice Guidelines Committee, Alexandria, VA, 2017 - 2018

Member, Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Focused Update, ASCO, Alexandria, VA, 2017 - 2018

MD Anderson Physician Network Consultant, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - Present

Member, SWOG CCDR Database Observational Study Working Group, 2015 - 2018

Member, ASCO Representative in the Consensus Guideline on margins for ductal carcinoma in situ cancer, ASCO/SSO/ASTRO, 2015 - 2016

Liaison Member, ASCO Quality of Care Committee, Alexandria, VA, 2014 - 2017

Member, ASCO Guideline Methodology Subcommittee, Alexandria, VA, 2014 - Present

Member, ASCO Clinical Practice Guideline Committee, Alexandria, VA, 2014 - 2017

Member, SWOG Cost-Effectiveness and Outcomes Committee, Portland, OR, 2013 - Present

Member, ASCO representative in the Consensus Guideline on margins for invasive breast cancer, SSO/ASTRO, 2013 - 2014

Member, National Breast Cancer Guideline Committee, Mexico, 2012 - Present

Member, SWOG Breast Committee, Portland, OR, 2011 - Present

Member, SWOG Breast Committee Working Group, Portland, OR, 2011 - Present

Medicine Chief Resident, John Cochran VA Medical Center, St. Louis, MO, 2007 - 2008

Study Coordinator, Departamento de Oncología, Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, 2004 - 2005

Institutional Committee Activities

Award Reviewer, V Foundation Women Scientist’s Innovation Award for Cancer Research, 2024 - Present

Member, Faculty Diversity Panel (FDP), 2022 - 2023

Internal Review-Selection Committee, Jack and Beverly Randall Excellence in Cancer Treatment Award, 2022 - Present

Co-chair, Pathology and Laboratory Medicine Division Head Search Committee, 2021 - Present

Member, Equity Workgroup, 2021 - 2021

Member, Breast Medical Oncology Survivorship/Workgroup, 2020 - Present

Member, Patient Experience Workgroup, Nellie B. Connally Breast Center, 2020 - Present

Member, Shared Resource Oversight Committee, 2020 - 2021

Member, Health Services Research Faculty Search Committee, 2018 - Present

Member, Health Disparities Research Faculty Search Committee, 2018 - Present

Member, Radiation Oncology Division Head Search Committee, 2018 - 2019

Medical Oncology Leader Liaison, MD Anderson Cancer Center Patient Advocate Initiative, 2017 - 2020

Member, Symptom Research Chair Search Committee, 2017 - 2017

Medical Oncology Advisor, Israelita Brasileira Hospital Albert Einstein Breast Tumor Board, 2017 - 2018

Medical Oncology Representative, Multidisciplinary Breast Evaluation Group Northwell, 2017 - 2018

Senator, Faculty Senate, 2016 - 2019

Member, Institutional Review Board IV, 2016 - 2018

Review Committee, Breast Moon Shot, 2016 - 2018

Member, Department of Health Services Research Faculty Search Committee, 2015 - 2017

Nomination Committee, Charles A. LeMaistre Lecture, 2015 - 2017

Member, Clinical Effectiveness Subcommittee (CE Subcommittee), 2015 - 2018

Member, Multidisciplinary Breast Cancer Relationship Committee, 2014 - Present

Member, Mexican-American Cohort Study Internal Advisory Board, 2014 - Present

Member, MD Anderson Cancer Center at Cooper (MDACCC) Relationship Committee, 2014 - Present

Member, Clinical Research Committee 3, 2008 - 2012

Honors & Awards

2024	Top 1% Nationally in CAHPS measures related to patient experience and satisfaction (100% Perfect Score), The University of Texas MD Anderson Cancer Center
2022	Komen Scholar, Susan G. Komen
2021	Elected, Member of The American Society of Medical Oncology Board of Directors
2021	Fellow of the American Society of Clinical Oncology, The American Society of Clinical Oncology
2020	Faculty Honoree, President’s Recognition of Faculty Excellence,Clinical Quality Improvement, The University of Texas MD Anderson Cancer Center
2020	Top 1% Nationally in CAHPS measures related to patient experience and satisfaction (100% Perfect Score), The University of Texas MD Anderson Cancer Center
2019	Top 10% Nationally in CAHPS measures related to patient experience and satisfaction, The University of Texas MD Anderson Cancer Center
2018	2018 Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2018	Academic Distinction for a Career in Breast Cancer Research, Best of ASCO Mexico
2017	Top 1% Nationally in CAHPS measures related to patient experience and satisfaction, The University of Texas MD Anderson Cancer Center
2015	Young Investigator Award, Multinational Association of Supportive Care in Cancer (MASCC)
2011	Achievement in Clinical Research Award, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
2011	Young Investigator Award, SWOG
2010	AACR/ASCO Methods in Clinical Cancer Research Workshop, Vail, Colorado
2009	ASCO Cancer Foundation Merit Award, The Breast Cancer Symposium
2009	AACR Minority Scholar, Susan G. Komen for the Cure
2008	Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
2008	Kipnis-Daughaday Teaching Award, Washington University School of Medicine
2006	Best Poster Award, Mentors in Medicine Research Grant Scientific Symposium. Washington University School of Medicine
2006	Clinical Scientist Training and Research Program, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO
2004	NIHES Award, Erasmus University Rotterdam, University of Amsterdam, Utrecht University, University of Nijmegen, National Institute of Public Health and Environment, Netherlands Cancer Institute
2003	Merit-based Academic CONACYT Scholarship, The National Council for Science and Technology. Mexico
2002	Achievement Medical Student Award, Universidad Nacional Autónoma de México
2001	Academic Distinction, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico

Professional Memberships

Women Who Conquer Cancer Sub-committee, American Society of Medical Oncology

2022 - Present

American Association for Cancer Research

2009 - Present

American Society of Clinical Oncology

2008 - Present

Mexican Society of Senology

2001 - Present

Selected Publications

Peer-Reviewed Articles

Sullivan M, Lei X, Karuturi M, Malinowski C, Giordano SH, Chavez‑MacGregor M. Use of adjuvant capecitabine in older patients with early‑stage triple‑negative breast cancer. Breast Cancer Res Treat, 2025. e-Pub 2025.
Winer EP, Levit LA, Basch E, Chavez Mac Gregor M, Dubois R, Eckhardt S, Ellis LM, Hudis CA, Schrag D, Speers C, Wilky BA, Tibbits M, Spence R, Garrett-Mayer E. Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers. J Clin Oncol JCO2402246, 2025. e-Pub 2025. PMID: 39928904.
Zhao H, Shen C, Laureano JJ, Lei X, Niu J, Giordano SH, Chavez Mac Gregor M. Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Res Treat 210(1):191-203, 2025. e-Pub 2025. PMID: 39576449.
So A, Yi M, Simons JM, Kuerer HM, Caudle A, DeSnyder SM, Bedrosian I, Nead KT, Chavez Mac Gregor M, Teshome M, Hunt KK. Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy. Ann Surg Oncol 32(2):922-930, 2025. e-Pub 2025. PMID: 39441324.
Kroll, JL, Jones, M, Ann-Yi, S, Chavez Mac Gregor, M, Bruera, E, Milbury, K. Parenting and Family Concerns of Couples Navigating Advanced Breast Cancer Exploring Discussions Around Parenting Challenges and Targets for Intervention. Psycho-oncology 34(1):e70069, 2025. e-Pub 2025. PMID: 39788929.
Smith, GL, Smith, BD, Wu, C, Shaitelman, SF, Chavez Mac Gregor, M, Murthy, RK, Kaiser, KW, Ku, K, Shi, JJ, Shete, S, Chen, YS, Volk, R, Giordano, SH, Shih, YT, Hoffman, K. Financial toxicity in breast cancer patients receiving regional nodal irradiation. Breast 78, 2024. e-Pub 2024. PMID: 39321504.
Milbury K, Ann-Yi S, Whisenant MS, Jones M, Li Y, Necroto V, Yousuf SD, Chavez Mac Gregor M, Meyers L, Bruera E. Supporting patients with advanced cancer and their spouses in parenting minor children: results of a randomized controlled trial. Oncologist, 2024. e-Pub 2024. PMID: 39703166.
Smith GL, Smith BD, Wu C, Shaitelman SF, Chavez Mac Gregor M, Murthy R, Kaiser K, Ku KS, Shi JJ, Shete SS, Chen Y, Volk RJ, Giordano SH, Shih YT, Hoffman KE. Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtype. Breast 78(103813), 2024. e-Pub 2024. PMID: 39321504.
Muppidi N, Adesoye T, Yi M, Sun SX, Chavez MacGregor M, Singh P, Karuturi M, Tamirisa N, Hunt KK, Teshome M. Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy. Ann Surg Oncol, 2024. e-Pub 2024. PMID: 39192013.
Torrecillas Torres, L, Arce-Salinas, C, Bargallo-Rocha, E, Bautista-Piña, V, Cervantes Sánchez, G, Chavez Mac Gregor, M, Flores-Balcázar, CH, Del Carmen Lara Tamburrino, M, Lluch-Hernández, A, Maffuz-Aziz, A, Pérez-Sánchez, VM, Poitevin, A, Salas González, E, Soto-Perez-de-Celis, E, Valero, V, Villaseñor Navarro, Y, Cárdenas Sánchez, J. Consenso mexicano de cáncer mamario. Manejo del cáncer de mama en poblaciones especiales. Gaceta Mexicana de Oncologia 23(4):234-245, 2024. e-Pub 2024.
Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby RM, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, Bekaii-Saab T, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez Mac Gregor M, Owonikoko TK, Lopes G, Aggarwal C, Lee AI, Choueiri TK. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncol Pract OP2400565, 2024. e-Pub 2024. PMID: 39374449.
Chavez Mac Gregor, M, Miao, J, Pusztai, L, Goetz, MP, Rastogi, P, Ganz, PA, Mamounas, EP, Paik, S, Bandos, H, Razaq, W, O'Dea, AP, Kaklamani, V, Silber, A, Flaum, LE, Andreopoulou, E, Wendt, AG, Carney, JF, Sharma, P, Gralow, J, Lew, DL, Barlow, W, Hortobagyi, GN. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer. Journal of Clinical Oncology 42(25):3012-3021, 2024. e-Pub 2024. PMID: 38833643.
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Chavez Mac Gregor M, Chidebe R, Cortés J, Curigliano G, Dent RA, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Franco Millan SX, Gilchrist J, Gligorov J, Gradishar WJ, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim S, Koppikar S, J Kuper-Hommel MJ, Lecouvet FE, Mason G, Mertz SA, Mueller V, Myerson C, Neciosup S, Offersen BV, Ohno S, Pagani O, Partridge AH, Penault-Llorca F, Prat A, Rugo HS, Senkus E, Sledge GW, Swain SM, Thomssen C, Vorobiof DA, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer EP. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 76(103756), 2024. e-Pub 2024. PMID: 38896983.
Tamirisa N, Lei X, Malinowski C, Li M, Bedrosian I, Chavez Mac Gregor M. Association of Medicaid Expansion with Reduction in Racial Disparities in the Timely Delivery of up-front Surgical Care for Patients with Early-Stage Breast Cancer. Annals of surgery 280(1):136-143, 2024. e-Pub 2023. PMID: 38099455.
Sullivan M, Lei X, Giordano SH, Chavez Mac Gregor M. Breast Cancer and severe COVID-19 outcomes. Breast Cancer Res Treat 206(2):307-316, 2024. e-Pub 2024. PMID: 38580882.
Leonard S, Jones AN, Newman L, Chavez MacGregor M, Freedman RA, Mayer EL, Mittendorf EA, King TA, Kantor O. Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial. Breast Cancer Research and Treatment 206(1):185-193, 2024. e-Pub 2024. PMID: 38649618.
Cacho-Díaz B, Valdés-Ferrer SI, Chavez Mac Gregor M, Salmerón-Moreno K, Villarreal-Garza C, Reynoso-Noverón N. Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer. Radiotherapy and Oncology 9(197):110379, 2024. e-Pub 2024. PMID: 38862080.
Cervantes Sánchez, G, Hernández-Barragán, T, Aldaco, F, Arce-Salinas, C, Bargallo-Rocha, E, Bautista-Piña, V, Chavez Mac Gregor, M, Garnica-Jaliffe, G, Flores-Balcázar, CH, Del Carmen Lara Tamburrino, M, Lluch-Hernández, A, Maffuz-Aziz, A, Pérez, PP, Pérez-Sánchez, VM, Poitevin, A, Salas González, E, Soto-Perez-de-Celis, E, Torrecillas Torres, L, Valero, V, Villaseñor Navarro, Y, Cárdenas Sánchez, J. Mexican breast cancer consensus. Management of advanced breast cancer. Gaceta Mexicana de Oncologia 23(2):49-62, 2024. e-Pub 2024.
Schlam I, Chavez Mac Gregor M. Best of the year: Advanced breast cancer in 2023. Breast 74(103677), 2024. e-Pub 2024. PMID: 38401422.
Schaverien M, Singh P, Smith B, Qiao W, Akay C, Bloom E, Chavez Mac Gregor M, Chu C, Clemens M, Colen J, Ehlers R, Hwang R, Joyner M, Largo R, Mericli A, Mitchell M, Shuck J, Tamirisa N, Tripathy D, Villa M, Woodward W, Zacharia R, Kuerer H, Hoffman K. Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical Trial. JAMA Network Open 7(4):e245217, 2024. e-Pub 2024. PMID: 38578640.
Milbury, K, Ann-Yi, S, Jones, M, Li, Y, Whisenant, M, Yousuf, S, Necroto, V, Chavez Mac Gregor, M, Bruera, E. Patients with advanced cancer and their spouses parenting minor children. Psycho-oncology 33(3), 2024. e-Pub 2024. PMID: 38411282.
Martín M, Lim E, Chavez Mac Gregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim S, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J. Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. Journal of Clinical Oncology 42(18):2149-2160, 2024. e-Pub 2024. PMID: 38537155.
Chatwal MS, Camacho P, Symington B, Rosenberg A, Hinyard L, Chavez Mac Gregor M, Gallagher C, El-Jawahri A, McGinnis M, Lee RT. Ethics of Patient-Clinician Boundaries in Oncology: Communication Strategies for Promoting Clinician Well-Being and Quality Patient Care. JCO Oncology Practice 20(8):1016-1020, 2024. e-Pub 2024. PMID: 38484207.
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez Mac Gregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer 42(9):994-1000, 2024. PMID: 38252901.
Bargalló-Rocha JE, Aguilar-Villanueva S, Ahumada-Pámanes C, Arce-Salinas C, Álvarez-Cano A, Baley-Spindel I, Bautista-Piña V, Cervantes-Sánchez G, Chávez-MacGregor M, Esparza-Arias N, Figueroa-Padilla J, Flores-Balcázar CH, Flores-Moreno SM, Maffuz-Aziz A, Maldonado-Magos F, Carmen Lara-Tamburrino MD, Lluch-Hernández A, Navarro-Santiesteban S, Pérez-Sánchez VM, Poitevín-Chacón A, Ruvalcaba-Limón E, Salas-González E, Sarricolea-Puch A, Celis ES, Torrecillas-Torres L, Valero-Castillo V, Navarro YV, Chávarri-Guerra Y, Cárdenas-Sánchez AJ. Mexican breast cancer consensus. Management of early breast cancer. Gac Mex Oncol 23(1):17-47, 2024. e-Pub 2024.
Milbury K, Ann-Yi S, Jones M, Li Y, Whisenant M, Yousuf S, Necroto V, Chavez Mac Gregor M, Bruera E. Patients with advanced cancer and their spouses parenting minor children: The role of the relationship context in parenting concerns 33(2):e6310, 2024. PMID: 38411282.
Kantor, O, King, TA, Jones, A, Glass, CC, Leonard, SJ, Ogayo, ER, Mayer, E, Chavez Mac Gregor, M, Newman, LA, Freedman, RA, Mittendorf, EA. ASO Visual Abstract. Annals of surgical oncology 31(2):1010-1011, 2024. e-Pub 2024. PMID: 37889405.
Bargallo-Rocha, E, Aguilar-Villanueva, S, Ahumada-Pámanes, C, Arce-Salinas, C, Álvarez-Cano, A, Baley-Spindel, I, Bautista-Piña, V, Cervantes Sánchez, G, Chavez Mac Gregor, M, Esparza-Arias, N, Figueroa-Padilla, J, Flores-Balcázar, CH, Flores-Moreno, SM, Maffuz-Aziz, A, Maldonado-Magos, F, Del Carmen Lara Tamburrino, M, Lluch-Hernández, A, Navarro-Santiesteban, S, Pérez-Sánchez, VM, Poitevin, A, Ruvalcaba-Limón, E, Salas González, E, Sarricolea-Puch, A, Soto-Perez-de-Celis, E, Torrecillas Torres, L, Valero-Castillo, V, Villaseñor Navarro, Y, Cárdenas Sánchez, J. Consenso mexicano de cáncer mamario. Manejo del cáncer de mama temprano. Gaceta Mexicana de Oncologia 23(1):30-61, 2024. e-Pub 2024.
Glass, CC, Pride, RM, Freedman, RA, Mayer, E, Ogayo, ER, Chavez Mac Gregor, M, King, TA, Mittendorf, EA, Kantor, O. ASO Visual Abstract. Annals of surgical oncology 31(1):391-392, 2024. e-Pub 2024. PMID: 37755569.
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez Mac Gregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol 42(9):994-1000, 2024. e-Pub 2024. PMID: 38252901.
Chavez Mac Gregor M, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez Mac Gregor M, Chopra R, Danso MA, Gomez HL, Homian NM, Kandil A, Kithaka B, Koczwara B, Moy B, Nakigudde G, Petracci FE, Rugo HS, El Saghir NS, Arun BK. Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline. JCO Global Oncology 10(e2300285):e2300285, 2024. e-Pub 2024. PMID: 38206277.
Chavez Mac Gregor M, Miao J, Pusztai L, Goetz M, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos S, Razaq W, O’Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopoulou E, Wendt AG, Carney JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN. Phase III randomized, placebo-controlled clinical trial of adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer. J Clin Oncol. e-Pub 2024.
Licata L, Viale G, Guiliano M, Curigliano G, Chavez Mac Gregor M, Foldi J, Oke O Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini OD, Cascinu S, Pusztai L, Giordano A, Cristiello C, Bianchini G. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. NPJ Breast Cancer 2023 9(1):51, 2023. e-Pub 2023. PMID: 37291235.
Kantor O, King TA, Jones A, Glass C, Leonard SJ, Ogayo ER, Mayer EL, Chavez Mac Gregor M, Newman LA, Freedman RA, Mittendorf EA. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial. Annals of surgical oncology 30(13):8404-8411, 2023. e-Pub 2023. PMID: 37777685.
Glass CC, Pride RM, Freedman RA, El M, Ogayo ER, Chavez Mac Gregor M, King TA, Mittendorf EA, Kantor O. Racial Disparities in Locorregional Recurrence in Postmenopausal Patients with Stage I-III Hormone Receptor-Positive Enrolled in the NSABP B-42 Clinical Trial. Ann Surg Oncol 30(13):8320-8326, 2023. e-Pub 2023. PMID: 37670122.
Sukumar S, J, Chavez Mac Gregor M. POSITIVE: Pregnancy after Breast Cancer Should Be Supported for Many, but Not All. NEJM Group, Breast Cancer Update:11-13, 2023. e-Pub 2023.
Chelariu-Raicu A, Piha-Paul SA, Chavez Mac Gregor M, Johnson J, Sawaya R, McAleer MF, NguyenA, Harnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Multidisciplinary Care of Large Brain Metastasis in a Patient with Hormone Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation. J Immunother Precis Oncol 6(3):158-161, 2023. e-Pub 2023. PMID: 37637237.
Adesoye T, Liao KP, Peterson S, Li L, Zorzi D, Holmes HM, Chavez Mac Gregor M, Giordano SH. Patient-reported outcomes in older breast cancer survivors with and without prior chemotherapy treatment. Cancer Medicine 12(17):17740-17752, 2023. e-Pub 2023. PMID: 37551136.
Kantor O, King T, Freedman R, Mayer E, Chavez Mac Gregor M, Korde L, Sparano J, Mittendorf E. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial. JAMA Surg 158(6):583-591, 2023. e-Pub 2023. PMID: 37043210.
Chavez Mac Gregor M, Lei X, Malinowski C, Zhao H, Shih YC, Giordano SH. Medicaid expansion, chemotherapy delays, and racial disparities among women with early-stage breast cancer. J Natl Can Inst 115(6):644-651, 2023. e-Pub 2023. PMID: 36794921.
Shi JJ, Lei X, Chen YS, Chavez Mac Gregor M, Bloom E, Schlembach P, Shaitelman SF, Buchholz TA, Kaiser K, Ku K, Smith BD, Smith GL. Socioeconomic Barriers to Randomized Clinical Trial Retention in Patients Treated with Adjuvant Radiation for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 116(1):122-131, 2023. e-Pub 2023. PMID: 36724858.
Spence RA, Hinyard L, Jagsi R, Jimenez RB, Lopez AM, Chavez Mac Gregor M, Spector-Bagdady K, Rosenberg A. Oncology Community Where Reproductive Healthcare is Limited by Law. J Clin Oncol 41(15):2852-2858, 2023. PMID: 36989462.
Plitcha JK, Thomas SM, Hayes DF, Chavez Mac Gregor M, Allison K, Fowler AM, Giuliano AE, Sharma P, Smith BS, van Eycken E, Edge SB, Hortobagyi GN. Novel Prognostic Staging System for Patients with de Novo Metastatic Breast Cancer. J Clin Oncol, 2023 41(14):2546-2560, 2023. e-Pub 2023. PMID: 36944149.
Bruera S, Lei X, Zhao H, Yazdany J, Chavez Mac Gregor M, Giordano SH, Suarez-Almazor ME. Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus. Lupus Sci Med 10(1):000750, 2023. e-Pub 2023. PMID: 36787921.
McKenzie, ND, Liu, R, Chiu, AV, Chavez Mac Gregor, M, Frohlich, D, Ahmad, S, Hendricks, CB. Exploring Bias in Scientific Peer Review. JCO Oncology Practice 18(12):791-799, 2022. e-Pub 2022. PMID: 36215686.
Jorgensen, K, Wilke, RN, Nichols, HB, Fu, S, Wu, C, Melamed, A, Brady, PC, Chavez Mac Gregor, M, Clapp, MA, Giordano, SH, Rauh-Hain, JA. Obstetric and Neonatal Outcomes 1 or More Years After a Diagnosis of Breast Cancer. Obstetrics and gynecology 140(6):939-949, 2022. e-Pub 2022. PMID: 36357983.
Malinowski C, Paredes E, Houston AJ, Chavez Mac Gregor M. Advice from One Patient to Another: Qualitative Analysis of Patients’ Perspectives About Chemotherapy Initiation. Dovepress 14(16):3283-3289, 2022. e-Pub 2022. PMID: 36540647.
McKenzie N, Liu R, Chiu A, Chavez Mac Gregor M, Frohlich D, Ahmad S, and Hendricks C. Exploring Bias in Scientific Peer Review: An ASCO Initiative. JCO Oncol Pract 18(12):791-799, 2022. e-Pub 2022. PMID: 3621586.
Rauh-Hain JA, Zubizarreta J, Nitecki R, Melamed A, Fu S, Jorgensen K, Brady P, Baker V, Chavez Mac Gregor M, Giordano S, Keating N. Survival Outcomes Following Pregnancy or Assisted Reproductive Technologies after Breast Cancer: A Population-Based Study. Cancer 128(17):3243-3253, 2022. e-Pub 2022. PMID: 35767282.
Shinn E, Busch B, Jasemi N, Lyman C, Toole T, Richman S, Symmans W, Chavez-MacGregor M, Peterson S, Broderick G. Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. Front Psychol 13(856813), 2022. e-Pub 2022. PMID: 35903747.
Malinowski C, Lei X, Zhao H, Giordano SH, Chavez Mac Gregor M. Association of Medicaid Expansion with Mortality Disparity by Race and Ethnicity Among Patients with De Novo Stage IV Breast Cancer. JAMA Oncol 2022 8(6):863-870, 2022. e-Pub 2022. PMID: 35389432.
Housten, AJ, Malinowski C, Harris CL, McNeill LH, Chavez Mac Gregor M. Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients: A Qualitative Analysis. Patient Prefer Adherence 2022 16:749-759, 2022. e-Pub 2022. PMID: 35345541.
Sosa A, Lei X, Woodward WA, Chavez Mac Gregor M, Lucci A, Giordano SH, Nead KT. Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US. JAMA Netw Open 5(2):e2148021, 2022. e-Pub 2022. PMID: 35147686.
Giordano, SH, Freedman, RA, Somerfield, MR, Chavez Mac Gregor, M, Comander, AH, Dayao, Z, Eisen, A, Gopalakrishnan, R, Graff, SL, Hassett, MJ, King, TA, Lyman, GH, Nunes, R, Perkins, CL, Telli, M, Trudeau, M, Wolff, AC. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer. Journal of Clinical Oncology 40(3):307-309, 2022. e-Pub 2022. PMID: 34878801.
Chavez Mac Gregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol 2022 8(1):69-78, 2022. e-Pub 2022. PMID: 34709356.
Oke O, Niu J, Chavez Mac Gregor M, Zhao H, Giordano SH. Adjuvant Tamoxifen Adherence in Men with Early-Stage Breast Cancer. Cancer 128(1):59-64, 2022. e-Pub 2022. PMID: 34597415.
Kantor O, Wang ML, Bertrand K, Pierce L, Freedman RA, Chavez Mac Gregor M, King TA, Mittendorf EA. Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. Ann Surg Oncol 29(1):686-696, 2022. e-Pub 2022. PMID: 34331158.
Nahlen Z, Layman GH, Schilsky RL, Peterson DE, Tagawa ST, Chavez Mac Gregor M. Use of Biosimilar Medications is Oncology. JCO Oncol Pract 2022 18(3):177-186, 2022. e-Pub 2022. PMID: 35041524.
Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, Engel J, Horton JK, King TA, Kornecki A, George R, SenGupta SK, Spears PA, Eisen AF. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol 39(27):3056-3082, 2021. e-Pub 2021. PMID: 34279999.
Moy B, Rumble BR, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi HN, Yee D, Smith IE, Chavez Mac Gregor M, Nanda R, McArthur LA, Spring L, Reedder-Hayes K, Ruddy JK, Unger PS, Vinayak S, Irvin WJ, Mrmaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol 29:JCO2101374, 2021. e-Pub 2021. PMID: 34324366.
Tamirisa N, Lei X, Caudle AS, Giordano SH, Zhao H, Chavez Mac Gregor M. Impact of SSO-ASTRO "No Ink on Tumor" Guidelines on Reexcision Rates among Older Breast Cancer Patients. Ann Surg Oncol 28(7):3703-3713, 2021. e-Pub 2021. PMID: 33225394.
Zhao H, Lei X, Niu J, Zhang N, Duan Z, Chavez Mac Gregor M, Giordano SH. Prescription Patterns, Initiation, and 5-Year Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Patients With Breast Cancer. JCO Oncol Pract 17(6):OP2000248, 2021. e-Pub 2021. PMID: 33596096.
Teshome M, Chavez Mac Gregor M. The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa-Maternal Orphans and a Cycle of Disadvantage. JAMA Oncol 7(2):197-198, 2021. e-Pub 2021. PMID: 33355608.
Denduluri N, Somerfield MR, Chavez Mac Gregor M, Comander AH, Dayao Z, Eisen A, Freedman RA, Gopalakrishnan R, Graff SL, Hassett MJ, King TA, Lyman GH, Maupin GR, Nunes R, Perkins CL, Telli ML, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. J Clin Oncol 39(6):JCO2002510, 2021. e-Pub 2021. PMID: 33079579.
Lim B, Song J, Ibrahim NK, Koenig KB, Chavez Mac Gregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(2):e230-e240, 2021. e-Pub 2021. PMID: 33140515.
Bardia A, Modi S, Oliveira M, Cortés J, Campone M, Ma BBY, Dirix LY, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant T, Rodriguez Lorenc CK, He W, Su F, Chavez Mac Gregor M. Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer. Clin Cancer Res 26(24):6417-6428, 2020. e-Pub 2020. PMID: 32998962.
Sharabi SE, Baumann DP, Selber JC, Killon E, Mericli AF, Liu J, Caudle AS, Smith BD, Chavez Mac Gregor M, Schaverien MV. Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?. Plast Reconstr Surg 146(5):945-953, 2020. e-Pub 2020. PMID: 33136936.
Sharma M, Duan Z, Zhao H, Giordano SH, Chavez Mac Gregor M. Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. Oncologist 25(11):937-942, 2020. e-Pub 2020. PMID: 32476216.
Smith-Graziani D, Lei X, Giordano SH, Zhao H, Karuturi M, Chavez Mac Gregor M. Delayed initiation of adjuvant chemotherapy in older women with breast cancer. Cancer Med 9(19):6961-6971, 2020. e-Pub 2020. PMID: 32767723.
Suarez-Almazor ME, Herrera R, Lei X, Chavez Mac Gregor M Zhao H, Giordano SH. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. Cancer 126(17):3929-3938, 2020. e-Pub 2020. PMID: 32573777.
de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez Mac Gregor M. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients. Oncologist 25(9):749-757, 2020. e-Pub 2020. PMID: 32431013.
Cacho-Díaz B, Salmerón-Moreno K, Alvarez-Alvarez A, Mendoza-Olivas LG, Alvarado-Miranda A, Villarreal-Garza C, Reynoso-Noverón N, Chavez Mac Gregor M, Meneses-García AA. Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms. Cancer 126(15):3456-3463, 2020. e-Pub 2020. PMID: 32453447.
Kantor O, Niu J, Zhao H, Giordano SH, Hunt KK, King TA, Mittendorf EA, Chavez Mac Gregor M. Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Ann Surg Oncol 27(7):2229-2237, 2020. e-Pub 2020. PMID: 31916091.
Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez Mac Gregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist 25(6):e909-e919, 2020. e-Pub 2020. PMID: 32003919.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez Mac Gregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 144(5):545-563, 2020. e-Pub 2020. PMID: 31928354.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez Mac Gregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 38(12):JCO1902309, 2020. e-Pub 2020. PMID: 31928404.
Shah MA, Oliver TK, Peterson DE, Einhaus K, Schneider BJ, Denduluri N, Chavez Mac Gregor M. ASCO Clinical Practice Guideline Endorsements and Adaptations. J Clin Oncol 38(8):JCO1902839, 2020. e-Pub 2020. PMID: 31841361.
Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez Mac Gregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. PLoS One 15(3):e0229903, 2020. e-Pub 2020. PMID: 32214335.
Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez Mac Gregor M, King TA, Mittendorf EA. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Ann Surg Oncol 27(2):359-366, 2020. e-Pub 2020. PMID: 31667721.
Adamson K, Chavez Mac Gregor M, Caudle A, Smith B, Baumann D, Liu J, Schaverien M. Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. Ann Surg Oncol 26(9):2730-2737, 2019. e-Pub 2019. PMID: 31037439.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez Mac Gregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21(1):78, 2019. e-Pub 2019. PMID: 31277699.
Avila J, Jupiter D, Chavez Mac Gregor M, de Oliveira C, Kaul S. High-Cost Hospitalizations Among Elderly Patients With Cancer. J Oncol Pract 15(5):e447-e457, 2019. e-Pub 2019. PMID: 30946640.
Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez Mac Gregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 37(10):JCO1802037, 2019. e-Pub 2019. PMID: 30702028.
Sharma M, Vadhariya A, Chikermane S, Gopinathan S, Chavez Mac Gregor M, Giordano SH, Johnson ML, Holmes HM. Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. Drugs Aging 36(4):341-354, 2019. e-Pub 2019. PMID: 30714077.
Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Invest New Drugs 37(2):345-351, 2019. e-Pub 2019. PMID: 30610588.
Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 24(3):313-318, 2019. e-Pub 2019. PMID: 30139836.
Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez Mac Gregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform 3:1-12, 2019. e-Pub 2019. PMID: 30892921.
Taylor JS, Zhang N, Rajan SS, Chavez Mac Gregor M, Zhao H, Niu J, Meyer LA, Ramondetta LM, Bodurka DC, Lairson DR, Giordano SH. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Gynecol Oncol 152(3):452-458, 2019. e-Pub 2019. PMID: 30876488.
Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez Mac Gregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2mm: Contemporary Outcomes With Breast Conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2019. PMID: 28742682.
Kehl KL, Niu J, Chavez Mac Gregor M, Giordano SH. Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. Cancer 124(24):4685-4691, 2018. e-Pub 2018. PMID: 30264853.
Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez Mac Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez Mac Gregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist 23(11):1300-1309, 2018. e-Pub 2018. PMID: 30139837.
DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez Mac Gregor M, Shen Y, Kuerer HM, Lucci A. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Ann Surg Oncol 25(10):2965-2974, 2018. e-Pub 2018. PMID: 29987598.
Cacho-Díaz B, Spínola-Maroño H, Arrieta VA, Granados-García M, Wegman-Ostrosky T, Mendoza-Olivas LG, Chavez Mac Gregor M. Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. Clin Neurol Neurosurg 173:61-64, 2018. e-Pub 2018. PMID: 30086430.
Namuche F, Ruiz RE, Morante Cruz ZD, Urrunaga D, Ziegler G, Mantilla R, Leon Rivera M, Chavez Mac Gregor M, Gomez Moreno HL. Oncotype Dx results in patients =40 years: Does age matter? New insights. Ann Oncol 29 Suppl 8:viii67-viii68, 2018. e-Pub 2018. PMID: 32137832.
Giordano SH, Duan Z, Zhao H, Hwang J, Chavez Mac Gregor M. Hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) screening prior to chemotherapy initiation among patients with solid tumors. Ann Oncol 29 Suppl 8:viii633, 2018. e-Pub 2018. PMID: 32137713.
Chavez Mac Gregor M, Lei X, Zhao H, van Poznak C, Giordano SH. Use of bone-modifying agents (BMA) and osteonecrosis of the jaw (ONJ) among older patients with metastatic breast cancer (BC). Ann Oncol 29 Suppl 8:viii115, 2018. e-Pub 2018. PMID: 32136136.
Henry ML, Niu J, Zhang N, Giordano SH, Chavez Mac Gregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging 11(8):1084-1093, 2018. e-Pub 2018. PMID: 30092967.
Unger JM, Moseley A, Symington B, Chavez Mac Gregor M, Ramsey SD, Hershman DL. Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials. JAMA Netw Open 1(4):e181235, 2018. e-Pub 2018. PMID: 30646114.
Denduluri N, Chavez Mac Gregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol 36(23):JCO2018788604, 2018. e-Pub 2018. PMID: 29787356.
Al-Sukhun S, Temin S, Chavez Mac Gregor M, Denduluri N, Oliver TK, Pyle D, Shah MA, Gralow J. ASCO Resource-Stratified Guidelines: Methods and Opportunities. J Glob Oncol(4):1-8, 2018. e-Pub 2018. PMID: 30110223.
de Melo Gagliato D, Chavez Mac Gregor M. Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?. Ann Surg Oncol 25(7):1786-1787, 2018. e-Pub 2018. PMID: 29600346.
Murthy RK, Chavez Mac Gregor M, Hortobagyi GN. Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. Curr Breast Cancer Reports(10):296-306, 2018. e-Pub 2018.
Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez Mac Gregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg 267(5):946-951, 2018. e-Pub 2018. PMID: 28549010.
Chavez Mac Gregor M, Unger JM, Moseley A, Ramsey SD, Hershman DL. Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. Cancer 124(8):1760-1769, 2018. e-Pub 2018. PMID: 29370458.
Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez Mac Gregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer 124(5):899-906, 2018. e-Pub 2018. PMID: 29236294.
Zhao H, Zhang N, Ho V, Ding M, He W, Niu J, Yang M, Du XL, Zorzi D, Chavez Mac Gregor M, Giordano SH. Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124(4):679-687, 2018. e-Pub 2018. PMID: 29140558.
Weiss A, Chavez Mac Gregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol 4(2):203-209, 2018. e-Pub 2018. PMID: 29222540.
Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez Mac Gregor M. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treat Rev 61:53-60, 2017. e-Pub 2017. PMID: 29100169.
Chavez Mac Gregor M, Mittendorf EA. Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. Lancet Oncol 18(12):1568-1569, 2017. e-Pub 2017. PMID: 29146400.
Mittendorf EA, Chavez Mac Gregor M, Vila J, Yi M, Lichtensztajn DY, Clarke CA, Giordano SH, Hunt KK. Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. Ann Surg Oncol 24(12):3502-3509, 2017. e-Pub 2017. PMID: 28726077.
Mittendorf EA, Chavez Mac Gregor M. All HER2-Positive Tumors are not Created Equal. Ann Surg Oncol 24(12):3471-3474, 2017. e-Pub 2017. PMID: 28815451.
Chavez Mac Gregor M, Mittendorf EA, Clarke CA, Lichtensztajn DY, Hunt KK, Giordano SH. Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. Oncologist 22(11):1292-1300, 2017. e-Pub 2017. PMID: 28592619.
Shih YT, Xu Y, Chavez Mac Gregor M, Guadagnolo BA, Smith BD, Giordano SH. Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage: An Analysis of Use of Radiation Therapy After Breast-Conserving Surgery. JAMA Oncol 3(10):1425-1426, 2017. e-Pub 2017. PMID: 28570719.
Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez Mac Gregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer 123(17):3367-3376, 2017. e-Pub 2017. PMID: 28518219.
Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez Mac Gregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. J Natl Cancer Inst 109(7), 2017. e-Pub 2017. PMID: 28376179.
Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez Mac Gregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer 123(13):2422-2431, 2017. e-Pub 2017. PMID: 28199747.
Zhao H, Hei N, Wu Y, Chan W, Lei X, Cameron C, Chang S, Chavez Mac Gregor M, Giordano SH. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer 123(6):940-947, 2017. e-Pub 2017. PMID: 27780311.
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez Mac Gregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol 3(4):509-515, 2017. e-Pub 2017. PMID: 27893038.
Vila J, Teshome M, Tucker SL, Woodward WA, Chavez Mac Gregor M, Hunt KK, Mittendorf EA. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg 265(3):574-580, 2017. e-Pub 2017. PMID: 27735826.
Candelaria RP, Huang ML, Adrada BE, Bassett R, Hunt KK, Kuerer HM, Smith BD, Chavez Mac Gregor M, Yang WT. Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. Acad Radiol S1076-6332(16):30396-8, 2017. e-Pub 2017. PMID: 27955877.
Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez Mac Gregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer 116(4):509-514, 2017. e-Pub 2017. PMID: 28081544.
Tuttle TM, Barrio AV, Klimberg VS, Giuliano AE, Chavez Mac Gregor M, Buum HA, McMasters KM. Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement. Ann Surg Oncol 24(1):1-2, 2017. e-Pub 2017. PMID: 27783164.
Kuerer HM, Smith BD, Chavez Mac Gregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez Mac Gregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol 34(33):4040-4046, 2016. e-Pub 2016. PMID: 27528719.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez Mac Gregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Ann Surg Oncol 23(12):3801-3810, 2016. e-Pub 2016. PMID: 27527714.
Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez Mac Gregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget 7(47):76362-76373, 2016. e-Pub 2016. PMID: 27806348.
Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez Mac Gregor M, Hunt KK, Meric-Bernstam F, Woodward WA. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys 96(3):637-44, 2016. e-Pub 2016. PMID: 27681760.
Cata JP, Chavez Mac Gregor M, Valero V, Black W, Black DM, Goravanchi F, Ifeanyi IC, Hernandez M, Rodriguez-Restrepo A, Gottumukkala V. The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. Reg Anesth Pain Med 41(6):696-703, 2016. e-Pub 2016. PMID: 27685344.
Giordano SH, Niu J, Chavez Mac Gregor M, Zhao H, Zorzi D, Shih YT, Smith BD, Shen C. Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. Cancer 122(22):3447-3455, 2016. e-Pub 2016. PMID: 27723214.
Vila J, Mittendorf EA, Farante G, Bassett RL, Veronesi P, Galimberti V, Peradze N, Stauder MC, Chavez Mac Gregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol 23(11):3501-9, 2016. e-Pub 2016. PMID: 27216742.
Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez Mac Gregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML, Schnitt SJ, Wapnir I, Moran MS. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Pract Radiat Oncol 6(5):287-95, 2016. e-Pub 2016. PMID: 27538810.
Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez Mac Gregor M. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 159(2):367-74, 2016. e-Pub 2016. PMID: 27522517.
Cleeland C, von Moos R, Walker MS, Wang Y, Gao J, Chavez Mac Gregor M, Liede A, Arellano J, Balakumaran A, Qian Y. Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Support Care Cancer 24(8):3557-65, 2016. e-Pub 2016. PMID: 27022965.
Mittendorf EA, Vila J, Tucker SL, Chavez Mac Gregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol 2(7):929-36, 2016. e-Pub 2016. PMID: 26986538.
Rosenstock AS, Lei X, Tripathy D, Hortobagyi GN, Giordano SH, Chavez Mac Gregor M. Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. Breast Cancer Res Treat 157(2):339-50, 2016. e-Pub 2016. PMID: 27146586.
Elting LS, Xu Y, Chavez Mac Gregor M, Giordano SH. Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. Support Care Cancer 24(6):2695-706, 2016. e-Pub 2016. PMID: 26797253.
Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, Tripathy D, Giordano SH, Chavez Mac Gregor M. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol 23(5):1515-21, 2016. e-Pub 2016. PMID: 26678405.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez Mac Gregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 34(10):1072-8, 2016. e-Pub 2016. PMID: 26811528.
Chavez Mac Gregor M, Giordano SH. Randomized Clinical Trials and Observational Studies: Is There a Battle?. J Clin Oncol 34(8):772-3, 2016. e-Pub 2016. PMID: 26786920.
Chavez Mac Gregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed Initiation of Adjuvant Chemotherapy among Patients with Breast Cancer. JAMA Oncol 2(3):322-9, 2016. e-Pub 2016. PMID: 26659132.
Chaudry M, Banchs J, Chavez Mac Gregor M. Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. Biomark Med 10(3):315-28, 2016. e-Pub 2016. PMID: 26860187.
Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez Mac Gregor M, Alvarez RH, Hortobagyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 21(1):21-7, 2016. e-Pub 2016. PMID: 26659222.
Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez Mac Gregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol 144(5):713-21, 2015. e-Pub 2015. PMID: 26486734.
Chaudry M, Lei X, Gonzalez-Angulo AM, Mittendorf EA, Valero V, Tripathy D, Hortobagyi GN, Chavez Mac Gregor M. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 153(2):417-23, 2015. e-Pub 2015. PMID: 26272743.
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez Mac Gregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 2015. e-Pub 2015. PMID: 26092296.
Chavez Mac Gregor M, Niu J, Zhang N, Elting LS, Smith BD, Banchs J, Hortobagyi GN, Giordano SH. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients with Breast Cancer. J Clin Oncol 33(19):2176-83, 2015. e-Pub 2015. PMID: 25964256.
Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez Mac Gregor M, Tripathy D, Gupta R, Varma A, Chouhan J, Guevarra RP, Valero V, Gilbert MR, Gonzalez-Angulo AM. Validation and Development of a Modified Breast Graded Prognostic Assessment as a Tool for Survival in Patients with Breast Cancer and Brain Metastases. J Clin Oncol 33(20):2239-45, 2015. e-Pub 2015. PMID: 25987700.
Bambhroliya A, Chavez Mac Gregor M, Brewster AM. Barriers to the Use of Breast Cancer Risk Reduction Therapies. J Natl Compr Canc Netw 13(7):927-35, 2015. e-Pub 2015. PMID: 26150584.
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez Mac Gregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and non-inflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):407-16, 2015. e-Pub 2015. PMID: 26017070.
Parinyanitikul N, Lei X, Chavez Mac Gregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AM. Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clin Breast Cancer 15(2):153-60, 2015. e-Pub 2015. PMID: 25454687.
Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez Mac Gregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget 6(5):2604-14, 2015. e-Pub 2015. PMID: 25605252.
Gonzalez-Angulo AM, Parinyanitikul N, Lei X, Mittendorf EA, Zhang H, Valero V, Hunt KK, Hortobagyi GN, Chavez Mac Gregor M. Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. Br J Cancer 112(4):630-5, 2015. e-Pub 2015. PMID: 25584488.
Rueth NM, Black DM, Limmer AR, Gabriel E, Huo L, Fornage BD, Dogan BE, Chavez MacGregor M, Yi M, Hunt KK, Strom EA. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol 22(1):90-5, 2015. e-Pub 2015. PMID: 25249256.
Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez Mac Gregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT. Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer 6(4):310-8, 2015. e-Pub 2015. PMID: 25767600.
Brewster AM, Chavez Mac Gregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15(13):e625-34, 2014. e-Pub 2014. PMID: 25456381.
Liu D, Shen Y, Ueno NT, Alvarez RH, Chavez Mac Gregor M, Woodward WA, Kogawa T, Babiera G. Factors influencing survival in inflammatory breast cancer 32(26_suppl):136, 2014. e-Pub 2014. PMID: 28141031.
Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez Mac Gregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?. Ann Surg Oncol 21(8):2468-73, 2014. e-Pub 2014. PMID: 24841348.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M, Surgical Oncology SO, Radiation Oncology ASF. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. J Clin Oncol 32(14):1507-15, 2014. e-Pub 2014. PMID: 24516019.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Ann Surg Oncol 21(3):704-16, 2014. e-Pub 2014. PMID: 24515565.
Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez Mac Gregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys 88(3):553-64, 2014. e-Pub 2014. PMID: 24521674.
Chavez Mac Gregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2014. e-Pub 2014. PMID: 24296856.
Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez Mac Gregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2014. e-Pub 2014. PMID: 24351399.
Shen MC, Massarweh NN, Lari SA, Vaporciyan AA, Selber JC, Mittendorf EA, Chavez Mac Gregor M, Smith BD, Kuerer HM. Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery. Ann Surg Oncol 20(13):4153-60, 2013. e-Pub 2013. PMID: 23959054.
Chavez Mac Gregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222-8, 2013. e-Pub 2013. PMID: 24127446.
Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez Mac Gregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378-84, 2013. e-Pub 2013. PMID: 23810431.
Lei X, Chavez Mac Gregor M, Mittendorf EA, Litton JK, Woodward WA, Zhang H, Hortobagyi GN, Gonzalez-Angulo AM. Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy (NCT) and analysis of survival outcome 31(26_suppl):48, 2013. e-Pub 2013. PMID: 28136644.
Chae YK, Hu MI, Katz RL, Chavez Mac Gregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 2013. e-Pub 2013. PMID: 23796991.
Litton J, Buzdar A, Chavez Mac Gregor M, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet 381(9883):2077-8, 2013. e-Pub 2013. PMID: 23769223.
Chavez Mac Gregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 119(9):1611-7, 2013. e-Pub 2013. PMID: 23341341.
Gonzalez-Angulo AM, Liu S, Chen H, Chavez Mac Gregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol 24(4):909-16, 2013. e-Pub 2013. PMID: 23139263.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Breast cancer in 2012: New drugs, new knowledge, new targets. Nat Rev Clin Oncol 10(2):75-6, 2013. e-Pub 2013. PMID: 23296111.
Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez Mac Gregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2013. PMID: 22736407.
Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez Mac Gregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. Springerplus 2:409, 2013. e-Pub 2013. PMID: 24156086.
Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez Mac Gregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer 4(7):549-56, 2013. e-Pub 2013. PMID: 23983819.
Gagliato D, Chavez Mac Gregor M. Adjuvant bisphosphonates in breast cancer: has the time come?. Breast Cancer Manage 2(4):327-337, 2013. e-Pub 2013.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Everolimus in the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs 21(12):1835-43, 2012. e-Pub 2012. PMID: 22994502.
Lynch SP, Lei X, Chavez Mac Gregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063-9, 2012. e-Pub 2012. PMID: 22776706.
Raghav KP, Wang W, Liu S, Chavez Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
Raghav KP, Hernandez-Aya LF, Lei X, Chavez Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2012. PMID: 21837669.
Chavez Mac Gregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mittendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer 118(2):326-32, 2012. e-Pub 2012. PMID: 21590688.
Chavez Mac Gregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 22(11):2394-402, 2011. e-Pub 2011. PMID: 21393379.
Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez Mac Gregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clin Breast Cancer 11(5):325-31, 2011. e-Pub 2011. PMID: 21764391.
Chavez Mac Gregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: A Surveillance, Epidemiology, and End Results-Medicare Study. Cancer 117(16):3641-9, 2011. e-Pub 2011. PMID: 21656514.
Melhem-Bertrandt A, Chavez Mac Gregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645-52, 2011. e-Pub 2011. PMID: 21632501.
Hernandez-Aya LF, Chavez Mac Gregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29(19):2628-34, 2011. e-Pub 2011. PMID: 21606433.
Chavez Mac Gregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AM. Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer 116(17):4168-77, 2010. e-Pub 2010. PMID: 20564153.
Chavez Mac Gregor M, González-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol 12(7):461-7, 2010. e-Pub 2010. PMID: 20615822.
Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez Mac Gregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11(5):421-8, 2010. e-Pub 2010. PMID: 20362507.
Chavez Mac Gregor M. Bone Therapy in Breast Cancer: Why, when and what's next?. The Breast Cancer Report 2(1), 2010. e-Pub 2010.
Chavez Mac Gregor M, Gonzalez-Angulo AM. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?. Clin Adv Hematol Oncol 7(9):591-8, 2009. e-Pub 2009. PMID: 20020671.
Chavez Mac Gregor M, Weilbaecher K, Aft R. Bone marrow micrometastases: Is there a role for bisphosphonates?. Breast Diseases: A Year Book Quarterly 19(4), 2009. e-Pub 2009.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumors. Br J Cancer 100:680-83, 2009. e-Pub 2009.
Chavez Mac Gregor M, van Gils CH, van der Schouw YT, Monninkhof E, van Noord PA, Peeters PH. Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108(1):101-12, 2008. e-Pub 2008. PMID: 18274909.
Ruvalcaba-Limón E, Robles-Vidal C, Poitevin-Chacón A, Chavez Mac Gregor M, Gamboa-Vignolle C, Vilar-Compte D. Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. Breast Cancer Res Treat 95(2):147-52, 2006. e-Pub 2006. PMID: 16319989.
Chavez Mac Gregor M, Aviles-Salas A, Green D, Fuentes-Alburo A, Gómez-Ruiz C, Aguayo A. Angiogenesis in the bone marrow of patients with breast cancer. Clin Cancer Res 11(15):5396-400, 2005. e-Pub 2005. PMID: 16061853.
Chavez Mac Gregor M, Elias SG, Onland-Moret NC, van der Schouw YT, Van Gils CH, Monninkhof E, Grobbee DE, Peeters PH. Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol Biomarkers Prev 14(4):799-804, 2005. e-Pub 2005. PMID: 15824146.
Vidal-Millan S, Zeichner-Gancz I, Flores-Estrada D, Vela-Rodríguez BE, Vazquez-López MI, Robles-Vidal CD, Ramirez-Ugalde MT, Chavez Mac Gregor M. A descriptive study of second primary malignancies associated to breast cancer in a Mexican Hispanic population. Med Oncol 22(1):17-22, 2005. e-Pub 2005. PMID: 15750192.
Ochoa-Carrillo FJ, Chavez Mac Gregor M, Green-Renner D, Green-Schneeweiss L. Paraneoplastic syndromes. Associated with lung cancer. Cir Cir 71(2):150-61, 2003. e-Pub 2003. PMID: 19764144.
Chavez Mac Gregor M, Ochoa-Carrillo F, Fuentes-Alburo A. Neurological Paraneoplastic Syndromes. Rev Inst Nal Cancerol 46(4):281-289, 2000. e-Pub 2000.

Book Chapters

Smith-Graziani, Chavez Mac Gregor M. Early Stage and Locally Advanced Breast Cancer. In: The MD Anderson Manual of Medical Oncology, Fourth Edition 4th Edition. 4th Edition. The MD Anderson Manual of Medical Oncology, 2021.
Karuturi M, Valero V, Chavez Mac Gregor M. Metastatic breast cancer. In: The MD Anderson Manual of Medical Oncology. 3rd Edition. McGraw Hill, 573-97, 2016.
Chavez Mac Gregor M, Hortobagyi GN. Metastatic breast cancer: A curable disease?. In: Breast Cancer Today. FEMA, 373-90, 2012.
Chavez Mac Gregor M, Gonzalez-Angulo AM. Metastatic Breast Cancer. In: Clinical Decision Support: Oncology, 2012.
Chavez Mac Gregor M, Gonzalez-Angulo AM, Hortobagyi GN. Breast Cancer Medical Therapy in High-Resource Countries. In: World Breast Cancer 2012. International Prevention Research Institute, 435-47, 2012.
Chavez Mac Gregor M, Valero V, Hortobagyi GN. Locally advanced breast cancer. In: Advanced Therapy of Breast Diseases. 3rd Edition, 855-876, 2012.
Chavez Mac Gregor M, Valero V. Metastatic breast cancer. In: The MD Anderson Manual of Medical Oncology, 679-710, 2011.
Chavez Mac Gregor M, Wildes TM. Breast cancer. In: Hematology and Oncology Subspecialty Consult, The Washington Manual Subspecialty Consult Series. 2nd edition, 189-203, 2008.

Less

Selected Presentations & Talks

Local Presentations

2022. Disparities in Breast Cancer: Treatment Differences and Consequences. Conference. Disparities in Breast Cancer: Treatment Differences and Consequences. Houston, TX, US.
2021. Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Cancer. Conference. Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Cancer. Houston, TX, US.
2021. Disparities in time to treatment. Conference. Disparities in time to treatment. Houston, TX, US.
2020. Special Issues in Breast Cancer. Conference. Special Issues in Breast Cancer. Houston, TX, US.
2020. Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Cancer. Conference. Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Cancer. Houston, TX, US.
2019. Special Issues in Breast Cancer. Conference. Special Issues in Breast Cancer. Houston, TX, US.
2019. Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Cancer. Conference. Treatment of Metastatic Breast Cancer Including HER2 Positive Breast Cancer. Houston, TX, US.
2019. Personalized Medicine HER 2. Conference. Personalized Medicine HER 2. Houston, TX, US.
2019. Advanced Breast Cancer. Conference. Advanced Breast Cancer. Houston, TX, US.
2015. Role of mTOR Inhibitors in the Treatment of Endocrine-Sensitive Metastatic Breast Cancer. Conference. Role of mTOR Inhibitors in the Treatment of Endocrine-Sensitive Metastatic Breast Cancer. Houston, TX, US.
2015. Genetic Counseling and Management of Breast Cancer in BRCA Carriers: Role of New Approaches in Testing. Conference. Genetic Counseling and Management of Breast Cancer in BRCA Carriers: Role of New Approaches in Testing. Houston, TX, US.
2014. Recent Advances in the Adjuvant and Neoadjuvant and Metastatic Treatment Options for Triple Negative Breast Cancer. Conference. Recent Advances in the Adjuvant and Neoadjuvant and Metastatic Treatment Options for Triple Negative Breast Cancer. Houston, TX, US.
2014. A basic introduction to breast cancer and treatment. Conference. A basic introduction to breast cancer and treatment. Houston, TX, US.
2013. A basic introduction to breast cancer and treatment. Conference. A basic introduction to breast cancer and treatment. Houston, TX, US.
2012. Comprehensive Board Review in Hematology and Medical Oncology. Conference. Comprehensive Board Review in Hematology and Medical Oncology. Houston, TX, US.

Regional Presentations

2021. The Disparity Crisis in Breast Cancer: Treatment Differences and Consequences. Conference. The Disparity Crisis in Breast Cancer: Treatment Differences and Consequences. El Paso, TX, US.
2020. Treatment differences and consequences. Conference. Treatment differences and consequences. San Antonio, TX, US.
2020. Cancer care delivery among breast cancer patients: Is it the same for all?. Conference. Cancer care delivery among breast cancer patients: Is it the same for all?. San Antonio, TX, US.
2019. Management of HR+/HER2- Early Stage Disease. Conference. Management of HR+/HER2- Early Stage Disease. Dallas, TX, US.
2019. Novel Approaches for Metastatic Triple-Negative Breast Cancer. Conference. Novel Approaches for Metastatic Triple-Negative Breast Cancer. Dallas, TX, US.
2018. Management of metastatic breast cancer. Conference. Management of metastatic breast cancer. Laredo, TX, US.

National Presentations

2023. I'm Diagnosed, Now What?. Conference. I'm Diagnosed, Now What?. Virtual, US.
2023. Exploratory biomarker analysis of acelERA Breast Cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC). Conference. ASCO. Chicago, IL, US.
2023. SWOG Latin American Initiative (SLAI): Progress and Directions. Conference. SWOG Latin American Initiative (SLAI): Progress and Directions. San Francisco, CA, US.
2023. Results of S1207 trial. Conference. Results of S1207 trial. Virtual Meeting, US.
2023. Advances in the Adjuvant Therapy for Breast Cancer. Conference. Advances in the Adjuvant Therapy for Breast Cancer. Steamboat Springs, CO, US.
2023. Susan G Komen's 2023 Health Equity Summit Highlights. Conference. Susan G Komen's 2023 Health Equity Summit Highlights, US.
2023. Disparities in Cancer Care Delivery. Conference. Disparities in Cancer Care Delivery, US.
2022. Incorporating overall survival and PFS into the decision-making process in the treatment of patients with metastatic HR+ breast cancer. Conference. Best of ASCO CDMX. Mexico City.
2022. Updates on Hormonal Receptor Positive HER2 Negative Breast Cancer. Conference. ASCO. Miami, FL, US.
2022. Research in Breast Cancer. Conference. Dr. Sana Al-Sukhun, US.
2022. Clinical trials for patients living with metastatic breast cancer, Komen MBC Impact Series,. Conference. Clinical trials for patients living with metastatic breast cancer, Komen MBC Impact Series,, US.
2022. ASCO 2022 Updates, After the ASCO Annual Meeting: What do I do Now?.Post-Annual Meeting Webinar. Conference. ASCO 2022 Updates, After the ASCO Annual Meeting: What do I do Now?.Post-Annual Meeting Webinar, US.
2022. Non-Traditional Career Paths, Women Networking Center. Conference. Non-Traditional Career Paths, Women Networking Center. Chicago, IL, US.
2022. HER2+ Breast Cancer: Metastatic Disease. Conference. Advances in Breast Cancer: Updates from ESMO and San Antonio. Virtual Meeting, US.
2022. Stump the Faculty. Conference. Advances in Breast Cancer: Updates from ESMO and San Antonio. Virtual Meeting, US.
2021. Updates on HER2-Positive Breast Cancer. Conference. ASCO. Miami, FL, US.
2021. YSC Summit: Ask the Expert: Hot-button Breast Cancer Updates, General Session Research and Treatment Advances in Breast Cancer for Young Adults. Conference. YSC Summit: Ask the Expert: Hot-button Breast Cancer Updates, General Session Research and Treatment Advances in Breast Cancer for Young Adults. Virtual Meeting, US.
2021. Breast Cancer Immunotherapy. Conference. 17th ANNUAL MIAMI CANCER MEETING (MCM). Miami, FL, US.
2020. New Directions in Adjuvant Endocrine Therapy. Conference. Advancing Cancer Care by Applying Molecular Medicine. New Orleans, LA, US.
2019. Advances in the Treatment of HER2+ Breast Cancer. Conference. Advances in the Treatment of HER2+ Breast Cancer. Breckenridge, CO, US.
2019. Results from the Taylor Rx Trial: Impact on Clinical Practice. Conference. Results from the Taylor Rx Trial: Impact on Clinical Practice. Breckenridge, CO, US.
2018. Updates on HER2 Positive Breast Cancer. Conference. Best of ASCO. Miami, FL, US.
2018. Scientific evidence on the use of taxanes in early and advanced breast cancer. Conference. Cali Breast Meeting. Santiago de Cali, US.
2018. Clinical Aspects of Escalating or De-escalating Adjuvant Therapy in HER2+ Breast Cancer. Conference. 2018 ASCO Annual Meeting, Educational Session. Chicago, IL, US.
2018. Advances in the treatment of HER2 breast cancer. Conference. 16th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2018. Gene expression based adjuvant therapy: Results of trials. Conference. 16th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2017. Advances in the Treatment of Her-2 Positive Breast Cancer. Conference. 15th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2017. Gene Expression Based Adjuvant Therapy: Results of Trials and Impact on Adjuvant Therapy Recommendations. Conference. 15th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
2015. New Drugs in the Management of Breast Cancer. Conference. 1st Annual Symposium on Advances in Oncology: Breast and Gynecologic Malignancies. Saginaw, MI, US.
2014. Cancer Care Outcomes in the Real World (Poster Discussant). Conference. Cancer Care Outcomes in the Real World (Poster Discussant), US.
2013. Sequencing of endocrine therapies. Conference. Sequencing of endocrine therapies. Orlando, FL, US.
2013. Margins in invasive breast cancer. Conference. Margins in invasive breast cancer. Chicago, IL, US.
2012. Shall we do less or sometimes do we need more? From: S1007 to S1207. Conference. Shall we do less or sometimes do we need more? From: S1007 to S1207. Phoenix, AZ, US.
2012. State of the Art: Individualization of molecular markers. Conference. State of the Art: Individualization of molecular markers. San Diego, CA, US.

International Presentations

2023. Impact of the Oncotype DX genomic platform in the medical treatment HR+ HER2- breast cancer with and without lymph node involvement. Conference. Impact of the Oncotype DX genomic platform in the medical treatment HR+ HER2- breast cancer with and without lymph node involvement. Caracas, VE.
2023. TNBC and Immunotherapy Developments in Breast Cancer. Conference. WCS (Winter Cancer Symposium). Rio Grande, PR.
2023. Her-2 Low: A new classification, a new era in breast cancer. Conference. Sociedad Panameña de Oncologia, US.
2023. New therapies in the treatment of patients with germline mutations. Conference. Sociedad Panameña de Oncologia, US.
2023. Best of SABCS 2022. Conference. Asociación Colombiana de Hematología y Oncología. Bogota, CO.
2022. Updates in triple negative breast cancer: Biomarkers and new therapies. Conference. Updates in triple negative breast cancer: Biomarkers and new therapies, AR.
2022. SWOG Latin America Initiative (SLAI). Conference. SWOG Latin America Initiative (SLAI), UY.
2022. Population-based Studies Using Real World Data. Conference. Population-based Studies Using Real World Data, UY.
2022. Treatment Strategies for HER2 + HR + Breast Cancer. Conference. Treatment Strategies for HER2 + HR + Breast Cancer. Virtual Meeting, CN.
2022. Early breast cancer 2022:Practice changing updates. Conference. Early breast cancer 2022:Practice changing updates, MX.
2022. Benefit over time with CDK 4/6 inhibitors in mBC HR+/HER2. Conference. Benefit over time with CDK 4/6 inhibitors in mBC HR+/HER2, MX.
2022. Redefining the Management of Early Breast Cancer gBRCAm Patients. Conference. Redefining the Management of Early Breast Cancer gBRCAm Patients, TT.
2022. Update in Triple Negative Breast Cancer Treatment (Early and Advanced). Conference. Update in Triple Negative Breast Cancer Treatment (Early and Advanced). Bogota, CO.
2022. SABCS Updates and Review. Conference. ACHO. Virtual, US.
2021. Evolution of CDK 4/6 Therapy in Breast Cancer. Conference. AHOMPR Annual Meeting 2021. San Juan, PR.
2021. BRCA mutation status as a biomarker among patients with metastatic disease. Conference. AAOC. Virtual Meeting, AR.
2021. New treatments in the management of metastatic HER2+ breast cancer. Conference. V Congreso Nacional Oncologia Y Jornadas Interdisciplinarias. Virtual Meeting, CL.
2021. Metastatic Hormone Receptor Positive Breast Cancer: State of the Art Treatment. Conference. Metastatic Hormone Receptor Positive Breast Cancer: State of the Art Treatment. Virtual Meeting, PE.
2021. Use of CDK inhibitors in the real-world. Conference. AAOC. Virtual Meeting, AR.
2021. Early Stage Breast Cancer. Conference. ASCO. Virtual Meeting, CO.
2021. Neoadjuvant chemotherapy as standard of care in the treatment of patients with HER2-positive breast cancer.Neoadyuvancia en Cáncer de Mama Her2 positivo. Conference. Neoadjuvant chemotherapy as standard of care in the treatment of patients with HER2-positive breast cancer.Neoadyuvancia en Cáncer de Mama Her2 positivo. Virtual Meeting, EC.
2021. Treatment of patients with residual disease after neoadjuvant chemotherapy. Conference. Hemato Oncólogos, Instituto de Oncología. Virtual Meeting, CO.
2021. Treatment of metastatic breast cancer in the setting of germline BCRA mutations. Conference. Treatment of metastatic breast cancer in the setting of germline BCRA mutations, US.
2021. New Options in Treatment for HER2+ Breast Cancer. Conference. New Options in Treatment for HER2+ Breast Cancer. Virtual Meeting, PR.
2020. Neoadjuvant treatment in triple negative tumors and adjuvant treatment post surgery. Conference. Instituto Universitario de Ciencias Biomédicas de Córdoba, Virtual Meeting. Buenos Aires, AR.
2020. Emerging Challenges in Advanced Breast Cancer: Systemic management of brain metastasis. Conference. Buenos Aires Breast Cancer Conference. Buenos Aires, AR.
2020. Best Sequencing Treatment in Triple Negative Advanced Breast Cancer. Conference. Buenos Aires Breast Cancer Conference 2020 (BABCC). Buenos Aires, AR.
2020. DNA Repair Damage and PARP Inhibition: PARP inhibitor as a part our daily clinical practice. Conference. DNA Repair Damage and PARP Inhibition: PARP inhibitor as a part our daily clinical practice. Buenos Aires, AR.
2020. HR-positive / HER2-negative Early Breast Cancer: Adjuvant endocrine therapy - For five years, ten years or more. Conference. Breast Cancer Conference. Buenos Aires, AR.
2020. Discussion Clinical Case. Conference. International Academic Oncology. Virtual Meeting, MX.
2020. Treatment path for pre and post-menopausal patients with advanced disease. Conference. International Academic Oncology. Virtual Meeting, MX.
2020. Challenges in the treatment of advanced disease. Conference. International Academic Oncology. Virtual Meeting, MX.
2020. Triple negative breast cancer: New biomarkers. Conference. XVII Congreso Nacional de Mastología. Virtual Meeting, US.
2020. New agents in the treatment of HER2+ metastatic breast cancer. Conference. XVII Congreso Nacional de Mastología. Virtual Meeting, US.
2020. The use of genomic signatures in the management of young breast cancer patients with early stage breast cancer. Conference. The use of genomic signatures in the management of young breast cancer patients with early stage breast cancer. Virtual Meeting, PE.
2020. Metastatic HER2 positive breast cancer: Management beyond trastuzumab, pertuzumab and TDM1. Conference. Metastatic HER2 positive breast cancer: Management beyond trastuzumab, pertuzumab and TDM1. Virtual Meeting, PE.
2020. Endocrine therapy and DCK inhibitors in combination for the treatment of HR-positive breast cancer. Conference. Endocrine therapy and DCK inhibitors in combination for the treatment of HR-positive breast cancer. Virtual Meeting, MX.
2020. Optimizing the results of anti-CDK in the treatment of breast cancer with positive hormonal receptor. Conference. Optimizing the results of anti-CDK in the treatment of breast cancer with positive hormonal receptor. Virtual Meeting, AR.
2020. Breast cancer management mistakes during pregnancy. Conference. Breast cancer management mistakes during pregnancy. Virtual Meeting, MX.
2020. Immunotherapy in breast cancer. Conference. Immunotherapy in breast cancer. Virtual Meeting, MX.
2020. Breast Cancer Updates – ASCO Highlights. Conference. Breast Cancer Updates – ASCO Highlights. Virtual Meeting, CO.
2020. Breast cancer treatment recommendations during the COVID-19 pandemic. Conference. Breast cancer treatment recommendations during the COVID-19 pandemic. Virtual Meeting, CO.
2019. Triple negative breast cancer management in 2020. Conference. Asociación Colombiana de Mastología. Cartagena, CO.
2019. Real life experience with CDK 4/6 inhibitors. Conference. Asociación Colombiana de Mastología. Cartagena, CO.
2019. Systemic Management of residual disease after neoadjuvant chemotherapy. Conference. Asociación Colombiana de Mastología. Cartagena, CO.
2019. Updates in the management of metastatic HER2+ breast cancer. Conference. Asociación Colombiana de Mastología. Cartagena, CO.
2019. Time to treatment and its importance for breast cancer patients. Conference. Asociación Colombiana de Mastología. Cartagena, CO.
2019. Best of ASCO/ESMO in hormone-receptor positive breast cancer. Conference. Best of ASCO/ESMO in hormone-receptor positive breast cancer. Merida, MX.
2019. Delay as an adverse prognostic factor in breast cancer. Conference. Delay as an adverse prognostic factor in breast cancer. Merida, MX.
2019. Difference between iCDK4/6 as 1st line treatment option in premenopausal women with metastatic breast cancer HR+ / HER2-. Conference. Difference between iCDK4/6 as 1st line treatment option in premenopausal women with metastatic breast cancer HR+ / HER2-. Merida, MX.
2019. Science to the service of breast cancer patients. Conference. Science to the service of breast cancer patients. Bogota, CO.
2019. Current therapies for early HER2+ and the importance of a multidisciplinary approach. Conference. Current therapies for early HER2+ and the importance of a multidisciplinary approach. Buenos Aires, AR.
2019. Neoadjuvant treatment for triple negative cancer. Conference. Neoadjuvant treatment for triple negative cancer. Buenos Aires, AR.
2019. Benefits and obstacles in guidelines application in clinical practice. Conference. Benefits and obstacles in guidelines application in clinical practice. Gdansk, PL.
2019. Evolving therapeutic standards in HR+/HER- mBC. Conference. Evolving therapeutic standards in HR+/HER- mBC. Mexico DF, MX.
2019. PARP Inhibitors and Breast Cancer. Conference. PARP Inhibitors and Breast Cancer. Lima, PE.
2019. Moving Towards Personalized Medicine in Breast Cancer from HER2 Neu Therapy to Triple Negative Tumors. Conference. Moving Towards Personalized Medicine in Breast Cancer from HER2 Neu Therapy to Triple Negative Tumors. Lima, PE.
2019. Immunotherapy in Breast Cancer. Conference. Immunotherapy in Breast Cancer. Bogota, CO.
2019. Genomic Profiling in Breast Cancer. Conference. Genomic Profiling in Breast Cancer. Bogota, CO.
2019. Breast cancer and pregnancy. Conference. Breast cancer and pregnancy. Mexico DF, MX.
2019. Molecular profiling in breast cancer as a prognostic tool. Conference. Molecular profiling in breast cancer as a prognostic tool. Mexico DF, MX.
2018. Fertility and breast cancer. Conference. VII Congreso Internacional de Oncologia del Interior. Cordoba, AR.
2018. Current neoadjuvant systemic therapy for triple negative cancer. Conference. VII Congreso Internacional de Oncologia del Interior. Cordoba, AR.
2018. Cyclin D Inhibitors: From evidence to experience. Conference. VII Congreso Internacional de Oncologia del Interior. Cordoba, AR.
2018. How to enhance response in 1st line therapy for patients with metastatic breast cancer. Conference. How to enhance response in 1st line therapy for patients with metastatic breast cancer. Merida, MX.
2018. Multidisciplinary management of breast cancer: The MD Anderson approach. Conference. Multidisciplinary management of breast cancer: The MD Anderson approach. Merida, MX.
2018. Highlights of triple negative breast cancer. Conference. Highlights of triple negative breast cancer. Cancun, MX.
2018. In situ ductal carcinoma updates. Conference. ASCO-Oncosalud. Lima, PE.
2018. Neoadjuvant treatment in HER2. Conference. Neoadjuvant treatment in HER2. Lima, PE.
2018. Breast Cancer Tumor Board. Conference. ASCO-Oncosalud. Lima, PE.
2018. New target in Triple Negative Breast Cancer. Conference. New target in Triple Negative Breast Cancer. Lima, PE.
2018. Eribulin for the treatment of metastatic breast cancer, beyond anthracyclines and taxanes. Conference. Best of ASCO. Mexico City, MX.
2018. Adjuvant therapy on the elderly. Conference. Cali Breast Meeting. Santiago de Cali, CO.
2018. Hormone therapy for young cancer patients. Conference. Cali Breast Meeting. Santiago de Cali, CO.
2018. Hormone therapy beyond 5 years: Who is eligible?. Conference. Cali Breast Meeting. Santiago de Cali, CO.
2018. Personalized therapy based on genomic tumoral changes. Conference. Cali Breast Meeting. Santiago de Cali, CO.
2018. Cost-effectiveness of breast cancer management. Conference. Cali Breast Meeting. Santiago de Cali, CO.
2018. How is breast cancer treated in my country?. Conference. Cali Breast Meeting. Santiago de Cali, CO.
2018. Management of advanced breast cancer ER + Her2. Conference. XI Santiago International Breast Cancer Symposium. Santiago de Chile, CL.
2018. Metastatic Breast Cancer: The medical oncologist point of view. Conference. XI Santiago International Breast Cancer Symposium. Santiago de Chile, CL.
2018. The benefits of neo-adjuvant therapy according to molecular subtypes. Conference. XI Santiago International Breast Cancer Symposium. Santiago de Chile, CL.
2018. Palbociclib, ribociclib or amebaciclib: Are all the same? Mechanisms of action and clinical results. Conference. XI Santiago International Breast Cancer Symposium. Santiago de Chile, CL.
2017. New targeted therapies. Conference. XX Brazilian Congress of Clinical Oncology. Rio de Janeiro, BR.
2017. Hormone therapy sequencing. Conference. XX Brazilian Congress of Clinical Oncology. Rio de Janeiro, BR.
2017. After tamoxifen and aromatase inhibitors: how can we improve results of adjuvant hormone therapy?. Conference. XX Brazilian Congress of Clinical Oncology. Rio de Janeiro, BR.
2017. Sexuality, fertility and pregnancy during and after adjuvant treatment: what we need to know in 2017. Conference. XX Brazilian Congress of Clinical Oncology. Rio de Janeiro, BR.
2017. Neoadjuvant treatment in HER2 Positive disease 2017: Is there a Better Regimen?. Conference. XX Brazilian Congress of Clinical Oncology. Rio de Janeiro, BR.
2017. Multidisciplinary management of patients with stage IV breast cancer and oligometastatic disease. Conference. XIV NATIONAL CONGRESS OF MASTOLOGY. Guadalajara, MX.
2017. Innovations and changes to the traditional anatomical TNM. Conference. XIV NATIONAL CONGRESS OF MASTOLOGY. Guadalajara, MX.
2017. The time to treatment as a prognostic determinant in Breast Cancer. Conference. 2nd Congreso de Actualidades en el Diagnóstico y Tratamiento del Cáncer de Mama. Ciudad de Mexico, MX.
2017. "Top Ten" in Medical Oncology: Breast Cancer. Conference. 2nd Congreso de Actualidades en el Diagnóstico y Tratamiento del Cáncer de Mama. Ciudad de Mexico, MX.
2017. Multidisciplinary Session "Metastatic Breast Cancer," 2nd Congreso de Actualidades en el Diagnóstico y Tratamiento del Cáncer de Mama. Conference. Instituto de Enfermedades de la Mama FUCAM. Ciudad de Mexico, MX.
2017. Current Anti CDK Therapy. Conference. XII Congreso Internacional de Terapias Biologicas. Queretaro, MX.
2017. New perspectives for the treatment of triple negative metastatic breast cancers. Conference. Breast Cancer Symposium. Paris, FR.
2017. How to make inferences and conclusions about Real World Data : A Guidance for clinicians using published article. Conference. MedicReS Vienna 2017. Vienna, AT.
2017. Importance of Selection of Outcomes and Covariates in Comparative Effectiveness Research of Cancer. Conference. MedicReS Vienna 2017. Vienna, AT.
2016. Management of Metastatic Hormone Receptor Breast Cancer. Conference. Instituto Jalisciense de Cancerologia. Guadalajara, MX.
2016. High Risk Patient BRACA 1 - BRACA 2: Study Indications. Conference. XXI Congreso Chileno de Cancerologia. Santiago de Chile, CL.
2016. Present and Future Treatment of Breast Cancer HER2 (+). Conference. XXI Congreso Chileno de Cancerologia. Santiago de Chile, CL.
2016. Breast Cancer HER2/ER+. Conference. Instituto Nacional de Cancerologia. Cancun, MX.
2016. Management of axillary positive nodes (1 to 3 Nodes) in invasive breast cancer. Conference. Best of Society of Surgical Oncology (SSO). Cancun, MX.
2016. Interactive multidisciplinary case presentation breast cancer. Conference. The Best of Society of Surgical Oncology (SSO). Cancun, MX.
2016. Management of multi-treated breast cancer. How long?. Conference. III Jornada de Oncologia Medica. Santiago de Chile, CL.
2016. Adjuvant treatment of the patient with early breast cancer: Chemotherapy or Hormonal therapy?. Conference. III Jornada de Oncologia Medica. Santiago de Chile, CL.
2016. Role of Immunotherapy in Breast Cancer. Conference. III Jornada de Oncologia Medica. Santiago de Chile, CL.
2016. Do all patients with positive nodes need systemic management?. Conference. XIII Congreso Nacional de Mastologia. Queretaro, MX.
2016. Updates in the management of breast cancer patients with febrile neutropenia. Conference. 1er Workshop de Investigación Clínica en Hemato Oncología. Cali, CO.
2016. Principles of biostatistics and Clinical trial design. Conference. 1er Workshop de Investigación Clínica en Hemato Oncología. Cali, CO.
2016. Observational studies. Conference. 1er Workshop de Investigación Clínica en Hemato Oncología. Cali, CO.
2016. Clinical trials: From sample size calculation to randomization and data collection. Conference. 1er Workshop de Investigación Clínica en Hemato Oncología. Cali, CO.
2016. Management of Triple Negative Breast Cancer. Conference. XI Congreso Internacional de Terapias Biológicas y Nuevas Drogas. Querétaro, MX.
2016. New Endocrine Alternatives for Breast Cancer Treatment. Conference. XI Congreso Internacional de Terapias Biológicas y Nuevas Drogas. Querétaro, MX.
2016. Best Use of Neadjuvant Therapy in Breast Cancer. Conference. XXXIII Reunión Anual del Instituto Nacional de Cancerología. Querétaro, MX.
2015. New treatment options for advanced breast cancer. Conference. 33rd National Congress. Cancun, MX.
2015. Hereditary breast cancer. Conference. 33rd National Congress. Cancun, MX.
2015. Endocrine resistance in breast cancer. Conference. Endocrine resistance in breast cancer. Cartagena, CO.
2015. Management of breast cancer during pregnancy. Conference. Management of breast cancer during pregnancy. Cartagena, CO.
2015. Local Therapy Breast Cancer. Conference. Local Therapy Breast Cancer. Cancun, MX.
2015. American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Conference. American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Mexico City, MX.
2015. Advances in the Multidisciplinary Management of Hereditary Cancer. Conference. 1er Simposio Cancer de Mama. Lima, PE.
2015. Mechanisms of Endocrine Resistance in Breast Cancer. Conference. Best of SABCS. Mexico City, MX.
2015. Management of Patients with Metastatic HER2-Positive Breast Cancer. Conference. Best of SABCS. Mexico City, MX.
2014. New breast cancer drugs. Conference. X Congreso Internacional de Mastología. Lima, PE.
2014. Timely management of neoadjuvant chemotherapy. Conference. X Congreso Internacional de Mastología. Lima, PE.
2014. Breast-Ovarian Cancer Syndrome. Conference. Breast-Ovarian Cancer Syndrome. Mexico DF, MX.
2014. New therapies for the management of metastatic HER2-positive breast cancer. Conference. New therapies for the management of metastatic HER2-positive breast cancer. Santiago de Cali, CO.
2014. New strategies in endocrine therapy: Management of endocrine resistance. Conference. New strategies in endocrine therapy: Management of endocrine resistance. Santiago de Cali, CO.
2014. Treatment of triple negative breast cancer: A clinical challenge. Conference. Treatment of triple negative breast cancer: A clinical challenge. Santiago de Cali, CO.
2014. Triple Negative Breast Cancer. Conference. Triple Negative Breast Cancer. Cancun, MX.
2014. Management of Metastatic Triple Negative Breast Cancer. New Alternatives. Conference. Management of Metastatic Triple Negative Breast Cancer. New Alternatives. Cancun, MX.
2014. Clinical Use of Genomic Platforms in Breast Cancer. Conference. Clinical Use of Genomic Platforms in Breast Cancer. Cancun, MX.
2014. New anti-Her2 therapies: Are they a real option?. Conference. New anti-Her2 therapies: Are they a real option?. Veracruz, MX.
2014. Clinical impact of primary prophylaxis for febrile neutropienia in breast cancer. Conference. Clinical impact of primary prophylaxis for febrile neutropienia in breast cancer. Jeju Island.
2014. Current Concepts in Breast Cancer. Conference. Current Concepts in Breast Cancer. Mexico City, MX.
2014. Breast Cancer and Pregnancy. Conference. Breast Cancer and Pregnancy. Mexico City, MX.
2014. Genomic profiles: Comparison and clinical use. Conference. Genomic profiles: Comparison and clinical use. Mexico City, MX.
2014. Breast cancer and pregnancy. Conference. Breast cancer and pregnancy. Mexico City, MX.
2013. Updates in the medical management of breast cancer. Conference. FUNAYUDA. Panama City, PA.
2013. Risk of recurrence and treatment of T1 a,b N0 breast cancer. Conference. Risk of recurrence and treatment of T1 a,b N0 breast cancer. Cartagena, CO.
2013. Breast cancer in the elderly. Conference. Breast cancer in the elderly. Mexico City, MX.
2013. Targeted therapies in the management of metastatic breast cancer. Conference. 1ra Jornada Oncológica Médica “Cáncer de Mama”. DF, MX.
2013. Targeted therapy in early stage breast cancer. Conference. Targeted therapy in early stage breast cancer. Cali, CO.
2013. Metastatic Breast Cancer: State of the Art. Conference. Metastatic Breast Cancer: State of the Art. Cali, CO.
2013. Breast Cancer. Conference. Best of ASCO 2013. Cancun, MX.
2013. Genomic platforms in breast cancer. Conference. Genomic platforms in breast cancer. Guanajuato, MX.
2013. Practice-changing advances in the care of breast cancer. Conference. Practice-changing advances in the care of breast cancer. Guanajuato, MX.
2012. Gene expression profiles in clinical practice. Conference. IX Congreso Nacional de Mastología. Villahermosa, MX.
2012. New molecular targets for the treatment of breast cancer. Conference. IX Congreso Nacional de Mastología. Villahermosa, MX.
2012. Current treatment strategies for the treatment of hormone receptor-positive metastatic breast cancer. Conference. XXX Congreso Nacional de Oncología. Guadalajara, MX.
2012. Multi-Disciplinary Approach in Breast Cancer. Conference. Multi-Disciplinary Approach in Breast Cancer. Nairobi, KE.
2012. Breast Cancer: Diagnosis, Staging and Therapy. Conference. Breast Cancer: Diagnosis, Staging and Therapy. Nairobi, KE.
2012. Selection of Breast Cancer Treatment during Chemoresistance. Conference. Selection of Breast Cancer Treatment during Chemoresistance. Cuernavaca, MX.
2012. State of the art in the management of metastatic breast cancer. Conference. State of the art in the management of metastatic breast cancer. Guadalajara, MX.
2011. State of the art in the use of aromatase inhibitors and biophosphonates. Conference. XI Congreso Venezolano de Mastología. Barquisimeto, VE.
2011. Research in breast cancer. Conference. XI Congreso Venezolano de Mastología. Barquisimeto, VE.
2011. Her2neu 1st and 2nd line of therapy. Conference. Her2neu 1st and 2nd line of therapy. Qro, MX.

Formal Peers

2021. The Disparity Crisis in Breast Cancer: Treatment Differences and Consequences. Visiting. The Disparity Crisis in Breast Cancer: Treatment Differences and Consequences. El Paso, TX, US.
2021. Guidelines for breast cancer diagnosis and treatment in Mexico. Invited. Guidelines for breast cancer diagnosis and treatment in Mexico. Colima, MX.
2019. Guidelines for breast cancer diagnosis and treatment in Mexico. Invited. Guidelines for breast cancer diagnosis and treatment in Mexico. Colima, MX.
2018. AJCC New Staging System: Staging System in Breast Cancer: Clinical and Practical Implications. Visiting. AJCC New Staging System: Staging System in Breast Cancer: Clinical and Practical Implications. Katy, TX, US.
2017. Breast Cancer Treatment Delays: Do They Matter?. Visiting. Breast Cancer Treatment Delays: Do They Matter?. Houston, TX, US.
2017. Guidelines for breast cancer diagnosis and treatment in Mexico. Invited. Guidelines for breast cancer diagnosis and treatment in Mexico. Colima, MX.
2016. Time to Treatment Among Breast Cancer Patients: The Sooner, the Better?. Visiting. Time to Treatment Among Breast Cancer Patients: The Sooner, the Better?. Houston, TX, US.
2016. Breast Cancer Treatment: The sooner, the better?. Visiting. Breast Cancer Treatment: The sooner, the better?. Houston, TX, US.
2014. Using administrative data to study cardiotoxicity and cardiac monitoring in cancer patients. Visiting. Using administrative data to study cardiotoxicity and cardiac monitoring in cancer patients. Houston, TX, US.
2013. Breast cancer adjuvant trials with everolimus: S1207. Invited. Breast cancer adjuvant trials with everolimus: S1207. San Francisco, CA, US.
2013. TORC1/2 inhibitors. Invited. TORC1/2 inhibitors. Paris, FR.
2013. Guidelines for breast cancer diagnosis and treatment in Mexico. Invited. Guidelines for breast cancer diagnosis and treatment in Mexico. Colima, MX.
2012. Endocrine resistance in metastatic breast cancer: Challenges and potential therapeutic strategies. Visiting. Endocrine resistance in metastatic breast cancer: Challenges and potential therapeutic strategies, MX.
2012. Cardiac monitoring in elderly trastuzumab-treated patients: A SEER and TCR study. Visiting. Cardiac monitoring in elderly trastuzumab-treated patients: A SEER and TCR study. Houston, TX, US.
2012. ER-positive Breast Cancer Clinical Trials Planning Meeting. Invited. ER-positive Breast Cancer Clinical Trials Planning Meeting. Bethesda, MD, US.
2008. Death, Culture and Medicine. Visiting. Death, Culture and Medicine. St. Louis, MO, US.
2004. Observational Studies. Invited. Observational Studies. Mexico City, MX.
2002. Benign Breast Tumors. Invited. Benign Breast Tumors. Juriquilla Qro, MX.
2002. Breast Pain. Invited. Breast Pain. Juriquilla Qro, MX.

Less

Grant & Contract Support

Date:	2024 - 2026
Title:	Parenting Support for Unpartnered Mothers Diagnosed with Advanced Cancer
Funding Source:	Victoria’s Secret Global Fund for Womens Cancer Career Development Award, in partnership with Pelotonia & AACR
Role:	Collaborator
ID:	FP00022752

Date:	2023 - 2024
Title:	Cancer Care Delivery: Impact and Associated Factors
Funding Source:	Breast Cancer Research Foundation
Role:	PI
ID:	BCRF-23-190

Date:	2022 - 2025
Title:	Understanding Cancer Care Delivery in Texas
Funding Source:	Victoria's Secret Global Fund for Women's Cancer's Rising Innovator Award in Partnership with Pelotonia & AACR
Role:	PI
ID:	1014472

Date:	2022 - 2023
Title:	Treatment Non-Completion Among Patients with Breast Cancer: Impact and Associated Factors
Funding Source:	Breast Cancer Research Foundation (BCRF)
Role:	PI
ID:	BCRF-22-190

Date:	2022 - 2024
Title:	Breast Cancer Treatment Initiation and Completion
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	PI
ID:	SAC220221

Date:	2021 - 2025
Title:	SWOG Network group Operations Center of the NCTN
Funding Source:	NIH/NCI
Role:	Principal Investigator-MDACC
ID:	U01 CA180888-08

Date:	2019 - 2024
Title:	Impact of predicted tumoral sensitivity on simulated and actual adherence to oral endocrine treatment and breast cancer outcome
Funding Source:	NIH
Role:	Co-I

Date:	2018 - 2023
Title:	Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications
Funding Source:	NIH
Role:	Co-I
ID:	R01 CA225647-01

Date:	2018 - 2024
Title:	Toxicities of Breast Cancer Treatment
Funding Source:	Susan G. Komen Breast Cancer Foundation
Role:	Co-I
ID:	SAC150061

Date:	2018 - 2019
Title:	Understanding barriers associated with treatment delays
Funding Source:	Institutional Research Grant
Role:	PI

Date:	2018 - 2022
Title:	Understanding barriers and decreasing the time to chemotherapy in a vulnerable population: Pilot study of a targeted intervention
Funding Source:	Conquer Cancer Foundation of the American Society of Clinical Oncology
Role:	PI

Date:	2018 - 2019
Title:	Association of Body Mass Index (BMI) with emergency room visits and chemotherapy-related hospitalizations among breast cancer patients treated in SWOG clinical trials
Funding Source:	NCORP Cancer Care Delivery and The Hope Foundation
Role:	PI

Date:	2017 - 2021
Title:	Clinical trial participation among older breast cancer patients
Funding Source:	American Cancer Society (ACS)
Role:	PI

Date:	2017 - 2021
Title:	Innovative machine learning methods in medical cost analysis
Funding Source:	NIH - Subcontract from Northwestern University
Role:	Co-I

Date:	2017 - 2019
Title:	Clinical trial participation among older breast cancer patients
Funding Source:	MDACC - Sabin Foundation
Role:	PI

Date:	2016 - 2019
Title:	Predictive modeling for the risk of cancer using large scale electronic health records
Funding Source:	Cancer Prevention Research Institute of Texas (CPRIT) - Subcontract with UTHSC - Houston
Role:	Co-I

Date:	2016 - 2017
Title:	Health Assessment to Advance Cancer Prevention, Screening, and Control in the MD Anderson Cancer Center’s Catchment Area: The State of Texas
Funding Source:	NIH/NCI
Role:	Co-I
ID:	3 P30 CA016672-41S6

Date:	2016 - 2022
Title:	Comparative Effectiveness Research on Cancer in Texas (CERCIT) 2.0: Project 2
Funding Source:	Cancer Prevention Research Institute of Texas (CPRIT) Subcontract with UT Medical Branch - Galveston
Role:	Co-I
ID:	RP160674

Date:	2016 - 2019
Title:	Clinical trial participation among older breast cancer patients
Funding Source:	Susan G. Komen for the Cure. Career Catalyst Award
Role:	PI

Date:	2016 - 2017
Title:	Racial Disparities among participants in SWOG randomized clinical trials. NCORP Cancer Care Delivery Pilot Award
Funding Source:	The Hope Foundation
Role:	PI

Date:	2015 - 2019
Title:	Finding Optimal Strategies to Manage Cardiotoxicity in Elderly Cancer Patients
Funding Source:	NIH
Role:	Co-I

Date:	2015 - 2020
Title:	Medical and Financial Toxicity among Patients with Breast Cancer: A Comparative Effectiveness Analysis
Funding Source:	Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO)
Role:	Co-I

Date:	2015 - 2016
Title:	Impact of Oncotype Dx testing on the timing of radiation therapy delivery among breast cancer patients: A population based study
Funding Source:	The Center for Radiation Oncology - Health Services Research Seed Grant
Role:	PI
ID:	2015-13015201-Y1

Date:	2014 - 2017
Title:	Adherence to oral therapy in a phase III randomized placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor-positive and Her2-negative breast cancer (S1207)
Funding Source:	American Society of Clinical Oncology (ASCO) Career Investigator Award
Role:	PI

Date:	2014 - 2016
Title:	CERCIT: Comparative Effectiveness Research on Cancer in Texas (P4: Quality of Supportive Care in Texas)
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP140020-P4

Date:	2013 - Present
Title:	Adherence to oral therapy in a phase III randomized placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high risk hormone receptor-positive and Her2-negative breast cancer (S1207)
Funding Source:	American Society of Clinical Oncology (ASCO) Cancer Foundation Career Development Award
Role:	PI

Date:	2011 - Present
Title:	Trastuzumab-related cardiotoxicity
Funding Source:	American Society of Clinical Oncology (ASCO) Young Investigator Award
Role:	PI

Date:	2011 - Present
Title:	Disparities in the Adherence, monitoring and toxicities of adjuvant trastuzumab
Funding Source:	Susan G. Komen for the Cure Catalyst Award on Disparities
Role:	PI

Date:	2011 - Present
Title:	Adherence, chemotherapy use and cardiac monitoring during adjuvant trastuzumab
Funding Source:	National Comprehensive Cancer Network (NCCN) Young Investigator Award
Role:	PI

Date:	2010 - 2012
Title:	CERCIT: Comparative Effectiveness Research on Cancer in Texas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Research Scholar
ID:	RP101207

Date:	2010 - Present
Title:	PI3K/AKT/mTOR-related protein expression in breast cancer between White, Mexican and Mexican-American women
Funding Source:	American Society of Clinical Oncology (ASCO) Young Investigator Award
Role:	PI

CV information above last modified March 18, 2025

Mariana Chavez Mac Gregor, M.D., MSC

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Other Articles

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Mariana Chavez Mac Gregor, M.D., MSC

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Other Articles

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer